Professional
Added to YB: 2026-09-17
Pitch date: 2026-06-30
ACUTAAS.NS [bullish]
Acutaas Chemicals Limited
Author Info
No bio for this author
Company Info
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally.
Market Cap
INR 277.0B
Pitch Price
N/A
Price Target
N/A
Dividend
0.07%
EV/EBITDA
50.74
P/E
72.03
EV/Sales
18.86
Sector
Pharmaceuticals
Category
growth
Baron Emerging Markets Fund Added On Portfolio Holding: Acutaas Chemicals Limited
ACUTAAS.NS (added to position): The position was increased on confidence that Acutaas can deliver compound revenue and earnings growth above 20% over the next three to five years. The company holds 50%-90% shares in several critical pharmaceutical intermediates, is expanding higher-margin CDMO work — including a long-term contract as primary intermediates vendor for Bayer’s darolutamide — and is entering electrolyte additives and semiconductor chemicals.
Read full article (1 min)